September 2022 | Targeted Therapies in Oncology

Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC

September 24, 2022

Clinical Articles

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.

As CLL Approaches Expand, Sequencing Questions Arise

September 22, 2022

Clinical Articles

Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.